CME Group (CME) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is a modest beat or in-line print — consensus has been revised down ~2.5% since the Q1 print, creating a lower bar, but the wildcard is whether the sharp June sell-off in CME shares (driven by the CEO succession announcement and CFTC perpetuals ruling) has already priced in a softer volume quarter relative to Q1's record ADV.

CME heads into Q2 2026 earnings against a consensus ADV estimate of ~30.3 million contracts/day — a meaningful step-down from Q1 2026's all-time record of 36.2 million, which management itself flagged as showing "a little bit of softer activity" in April. The bar is therefore not high on volumes, and the key question is whether RPC (rate per contract) can stabilize after Q1's compression to $0.652 from volume tiering and micro-product mix shift. Estimate revisions have drifted modestly lower since the Q1 print (Q2 EPS consensus fell from ~$2.97 to ~$2.90), suggesting the Street has already absorbed the softer volume trajectory, but has not yet fully priced in the potential RPC recovery that could come if crude/nat gas mix normalizes. The stock has declined ~17% since Q1 earnings (April 22), dramatically underperforming the S&P 500 (+5%) and KBE (+9%), with the bulk of the damage concentrated in June following the June 17 CEO succession announcement (Lynne Fitzpatrick to succeed Terry Duffy effective no earlier than March 1, 2027) and the CFTC's May 29 approval of Kalshi's Bitcoin perpetual contract — both of which injected leadership uncertainty and competitive/regulatory risk premium into the stock. The single biggest wildcard is whether management provides any incremental color on the perpetuals regulatory landscape and its implications for CME's institutional franchise, as Duffy's June 4 Piper Sandler commentary was notably combative and the market has not yet settled on a view.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar — Q2 ADV of ~30.3M contracts is well below Q1's record 36.2M, and EPS of $2.90 is ~14% below Q1's $3.36. The bigger swing factor is RPC, where consensus at $0.713 implies a recovery from Q1's $0.652 low — if volumes come in above the ~30.3M estimate but RPC stays compressed, the revenue beat may be smaller than the volume beat implies.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 21, 2026. Q1 2026 actuals and Q2 2025 actuals from Visible Alpha reported figures.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: ADV & Operating EPS)

Pattern: CME has consistently missed ADV consensus over the last 8 quarters (7 of 8 misses), while beating or matching on EPS in 5 of 8 quarters — suggesting the Street systematically over-estimates volumes but CME's cost discipline and RPC management allow it to protect earnings. This pattern implies the Q2 ADV miss risk is already embedded in consensus, and the EPS beat probability is moderate.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: No formal guidance revisions have been issued since the Q1 2026 earnings call (April 22, 2026). The only post-earnings guidance-relevant event was the June 17 CEO succession announcement, which introduces leadership transition risk but does not alter financial guidance. Full-year adjusted expense guidance of $1.695B (excl. license fees) remains intact.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Q2 2026 EPS estimates have drifted ~2.5% lower since the Q1 print (from $2.97 to $2.90), while ADV estimates have been revised slightly higher (+1.2%), suggesting the Street is modeling a modest RPC recovery but trimming overall revenue expectations. FY 2026 estimates have also edged down ~0.7%, consistent with a softer-than-Q1 volume environment for the remainder of the year. The gap between current consensus and Q1’s record pace is the cushion — any upside surprise in June volumes or RPC could drive a beat.

Source: Visible Alpha Consensus and Actuals Data. Post-Q1 baseline uses April 24, 2026 as-of date (approximately 5 trading days after April 22, 2026 earnings). Current estimates as of July 21, 2026.

Commentary: The revision pattern is consistent with a market that has absorbed the Q1 volume record as a one-time peak and is now modeling a more normalized Q2 environment. The slight upward revision to ADV estimates (from 29.89M to 30.26M) alongside the downward EPS revision suggests the Street is modeling RPC compression persisting even as volumes recover modestly from April’s soft start. The FY 2026 ADV revision higher (+1.0%) reflects the strong open interest backdrop (management cited ~135M contracts at the June 2026 conference, the highest in company history), which supports a constructive volume outlook for H2 2026.

5. Stock Performance

Key Takeaway: CME has dramatically underperformed since Q1 earnings — down ~17% vs. S&P 500 +5% and KBE +9% — driven almost entirely by multiple compression (NTM P/E contracted from ~23x to ~20x) rather than estimate cuts. The stock’s de-rating reflects two discrete shocks: the CFTC’s May 29 perpetuals ruling and the June 17 CEO succession announcement, both of which injected structural uncertainty into what had been a premium-multiple story.

CME vs. KBE vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (April 22, 2026). Source: Yahoo Finance / Stock Price Data.

Performance Summary (April 22 – July 21, 2026):

• CME: $285.71 → $237.38, -16.9%
• KBE (SPDR S&P Bank ETF): $63.77 → $69.55, +9.1%
• SPY (S&P 500): $711.21 → $748.28, +5.2%

Key Events During the Period:

• May 29, 2026: CFTC approved Kalshi’s Bitcoin perpetual futures contract via 40.3 full review — a material regulatory development that Duffy called deeply concerning. CME shares fell sharply in the days following.
• June 4, 2026: Duffy at Piper Sandler conference delivered combative commentary on perpetuals, arguing they are structurally incompatible with institutional hedging and inconsistent with the Commodity Exchange Act.
• June 17, 2026: CME announced CEO succession — Lynne Fitzpatrick to succeed Duffy as CEO effective no earlier than March 1, 2027. Shares fell sharply on the announcement, with the stock declining from ~$261 to ~$225 over the following week.
• July 9, 2026: CFTC stayed CME’s self-certification for 24/7 crude oil futures, blocking the planned extension of round-the-clock trading to crude oil pending a full regulatory review.
• July 1–21, 2026: Partial recovery from the June lows ($218.58 on June 29 to $237.38 on July 21), likely driven by earnings anticipation and broader financial sector strength.

Decomposition: Over the 3-month period, CME’s NTM EV/EBITDA contracted from ~20.3x to ~18.3x (-11.7%), while NTM P/E contracted from ~23.0x to ~20.1x (-12.6%). Estimate cuts account for only ~0.7% of the EPS decline, meaning the vast majority of the stock’s underperformance is multiple compression — a sentiment/risk premium shift rather than a fundamental earnings deterioration. This creates a potential setup for re-rating if Q2 results are in-line and management provides reassuring commentary on the perpetuals/regulatory landscape and the CEO transition.

Source: Yahoo Finance Stock Price Data; Visible Alpha Consensus and Actuals Data (NTM multiples).

6. Material News & Developments (Since Q1 2026 Earnings, April 22, 2026)

Key Takeaway: The two most consequential developments since Q1 earnings are the CFTC’s approval of Bitcoin perpetual futures (May 29) and the CEO succession announcement (June 17) — both of which are structural/strategic in nature and will dominate the Q2 earnings call narrative. The CFTC’s subsequent blocking of CME’s 24/7 crude oil extension (July 9) adds a third regulatory overhang heading into the print.

• June 17, 2026 — CEO Succession Announced (Effective Date: No Earlier Than March 1, 2027): CME’s Board approved (June 16) and publicly announced (June 17) that Lynne Fitzpatrick (current President & CFO, age 48) will succeed Terry Duffy as CEO. Duffy will become Executive Chairman through December 31, 2027. Fitzpatrick’s CEO compensation: $1.2M base salary, 200% bonus target, 700% LTI target. A CFO search will be initiated. Implication: Leadership transition risk is now a live investor concern. Fitzpatrick is an internal candidate with deep CME tenure (since 2006) and strong financial credentials, but the market has historically penalized exchange stocks during CEO transitions. The Q2 call will be the first opportunity for management to address investor concerns about strategic continuity.
• May 29, 2026 — CFTC Approves Kalshi Bitcoin Perpetual Futures (Effective: May 29, 2026): The CFTC approved Kalshi’s Bitcoin perpetual contract via a 40.3 full review — a process Duffy argued was completed faster than a standard self-certification. CME management views perpetuals as structurally incompatible with institutional hedging (funding rate erosion) and inconsistent with the Commodity Exchange Act’s definition of a futures contract. CME has not committed to listing or not listing perpetuals if they become the regulatory norm. Implication: This is the single most important regulatory development for CME’s long-term competitive positioning. The Q2 call will likely include pointed analyst questions on CME’s response strategy.
• July 9, 2026 — CFTC Blocks CME’s 24/7 Crude Oil Futures Extension: The CFTC exercised its authority to stay CME’s self-certification for 24/7 crude oil futures (filed July 8), citing an ongoing public comment period on round-the-clock trading. CME had announced in June that it would offer 24/7 trading in crude and gold futures pending regulatory review. Implication: A near-term revenue opportunity is delayed. The CFTC’s action also signals heightened regulatory scrutiny of CME’s product innovation pipeline, which could slow the rollout of other new products.
• May 29, 2026 — 24/7 Crypto Trading Goes Live: CME launched 24/7 crypto futures trading on schedule, with meaningful contract volume traded over the inaugural weekend. Implication: A positive execution milestone; management will likely provide Q2 volume data for this new product on the earnings call.
• April 30, 2026 — CME-FICC Cross-Margining Expansion to End-Users Goes Live: The SEC and CFTC approved the expansion of the CME-FICC cross-margining program to end-user clients, with the first clearing member going live April 30. Management cited potential savings of up to 80% for client books. Implication: A key competitive differentiator that could drive client stickiness and open interest growth in Treasury futures. Adoption progress will be a key Q2 call topic.
• April 27, 2026 — CME Amends $7B Credit Facility: CME amended its $7 billion credit facility to bolster clearing house liquidity (8-K filed April 27, 2026). Implication: Routine balance sheet management; no material financial impact.
• June 4, 2026 — Piper Sandler Conference (Duffy): Duffy provided extensive commentary on perpetuals, single stock futures relaunch (~50 top U.S. companies), Silicon Data compute futures partnership, event contracts (>$270M contracts traded, >150,000 new accounts since December 2025), and capital allocation priorities. Implication: Confirms the strategic roadmap is intact; the combative tone on perpetuals signals CME will fight the regulatory battle aggressively.
• July 16, 2026 — CME Launches 90% and 50% Beef Trim Futures and Options: New contracts designed to track processed beef products used in ground beef production, addressing a gap in the existing cattle futures complex. Implication: Incremental product innovation in the agricultural complex; consistent with CME’s strategy of expanding its commodity product suite.
• July 9, 2026 — S&P DJI / HyperLiquid IP Dispute Ongoing: S&P Dow Jones Indices listed S&P 500 perpetual futures on HyperLiquid without prior notice to CME, which management views as confirmed IP/license infringement. Legal action is underway. Implication: A potential source of headline risk; resolution timeline uncertain. Management has indicated it expects to reach a resolution but it may take time.

7c. Macro Read-Through

• Fed Policy Uncertainty (July 2026): Multiple Fed officials (Cleveland Fed’s Hammack, Kansas City Fed’s Schmid) have signaled inflation remains "too hot," with markets pricing a ~59-87% probability of a September rate hike at various points in July. Rate hike uncertainty is a structural positive for CME’s interest rate derivatives franchise — elevated uncertainty drives hedging demand. CME’s FedWatch tool itself was cited in news coverage as the reference for rate hike probabilities, underscoring the franchise’s centrality to rate markets.
• AI Capital Expenditure Super Cycle: Goldman Sachs and Morgan Stanley both highlighted the AI CapEx super cycle as a defining theme, with data center CapEx projections rising from $575B to $850B+ for 2026. This drives elevated capital formation, financing activity, and hedging demand across interest rate, equity, and energy markets — all positive for CME volumes.
• Geopolitical Risk (Middle East, Russia-Ukraine, Taiwan): Duffy at the June 4 Piper Sandler conference cited geopolitical risk as "absolutely the biggest risk that the world has." ICE’s Sprecher noted Middle East tensions and Venezuela supply chain rewiring as drivers of energy hedging demand. Elevated geopolitical risk is a structural positive for CME’s energy and rates franchises.

Source: SEC Form 4 Filings Database. Transaction dates reflect actual execution dates; filing dates reflect SEC disclosure dates.

Analysis: Duffy’s May 15 sale is the most notable transaction. While not under a 10b5-1 plan, it is difficult to draw strong conclusions given that the CEO succession was not publicly announced until June 17 — the sale predates the announcement by ~33 days. Shepard’s June 25 purchase near the post-announcement lows is a modest positive signal. The absence of any insider buying by Fitzpatrick (the incoming CEO) or other senior executives is notable but not unusual given the pending leadership transition and potential blackout periods.

9. Key Risks & Questions for the Call

Key Risks

• RPC Compression Persistence: If Q2 volumes come in above consensus but RPC remains compressed (below $0.713 consensus), the revenue beat will be smaller than the volume beat implies. The mix shift toward micro products, crude vs. nat gas, and member trading are structural features that management has acknowledged but the market remains skeptical about.
• Perpetuals Regulatory Escalation: If the CFTC moves to formally regulate perpetuals as futures (rather than swaps), CME could face pressure to list them or risk losing market share to Kalshi and DeFi venues. Management has not committed to listing perpetuals, creating strategic uncertainty.
• CEO Transition Execution Risk: Fitzpatrick’s transition to CEO (effective no earlier than March 1, 2027) creates a ~9-month lame-duck period for Duffy. The simultaneous CFO search adds a second leadership vacancy. Investor confidence in strategic continuity will depend heavily on Q2 call messaging.
• 24/7 Crude Oil Regulatory Delay: The CFTC’s July 9 stay of CME’s 24/7 crude oil self-certification delays a near-term revenue opportunity and signals heightened regulatory scrutiny of CME’s product innovation pipeline.
• Volume Seasonality: Q2 is historically a softer quarter for CME (Q2 2025 ADV of 30.22M was below Q1 2025’s 29.77M on a seasonal basis). If June volumes were particularly weak (the stock’s sharp decline in June may reflect real-time volume data), the Q2 ADV could come in below the 30.26M consensus.
• S&P DJI / HyperLiquid IP Dispute: If the legal dispute with S&P Dow Jones Indices over the HyperLiquid S&P 500 perpetual futures is not resolved quickly, it could create ongoing headline risk and potentially limit CME’s ability to enforce its index licensing agreements.

Key Questions for the Q2 2026 Earnings Call

1. RPC Trajectory: What was the Q2 2026 average rate per contract, and how should we think about the structural vs. cyclical components of the compression from Q1’s $0.652? Is there a floor, and what mix conditions would drive recovery toward the $0.74-0.76 range seen in 2025?
2. Perpetuals Strategy: Has CME’s position on listing perpetuals evolved since the June 4 Piper Sandler conference? What is the company’s regulatory engagement strategy with the CFTC, and what is the timeline for resolution?
3. CEO Transition: What is the CFO search timeline and process? How will strategic decision-making be structured during the transition period? Will Fitzpatrick’s priorities as CEO differ from Duffy’s on key initiatives (perpetuals, single stock futures, tokenization)?
4. 24/7 Crude Oil: What is the status of the CFTC review of CME’s 24/7 crude oil self-certification? What is the expected timeline for resolution, and what is the revenue opportunity if approved?
5. CME-FICC Cross-Margining Adoption: How many clearing members have signed up for the end-user cross-margining program since the April 30 go-live? What is the pipeline, and what is the expected timeline for meaningful client book savings to materialize?
6. Event Contracts / Prediction Markets: What were Q2 2026 volumes and new account additions for the event contracts platform? Has the mix continued to shift toward market-based contracts (equity, crypto, energy) vs. sports contracts?
7. 24/7 Crypto Volume: What were the Q2 2026 volumes for 24/7 crypto trading since the May 29 launch? Is the institutional adoption tracking management’s expectations?
8. Open Interest: Management cited ~135M contracts of open interest at the June 2026 conference, the highest in company history. How has open interest trended through Q2, and what does this imply for H2 2026 volume expectations?
9. Expense Guidance: Is the $1.695B full-year adjusted expense guidance (excl. license fees) still intact? What is the Q3 expense run-rate expectation given the Dallas facility opening and ag product cloud migration?
10. Capital Return: What is the status of the OSTTRA proceeds deployment ($758M remaining at Q1 end)? Is the pace of share repurchases expected to continue at Q1’s $536M quarterly rate?